MoonLake Immunotherapeutics reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 36.01 million compared to USD 49.97 million a year ago. Basic loss per share from continuing operations was USD 0.73 compared to USD 1.7 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.92 USD | -2.50% | -9.59% | -32.24% |
May. 07 | MoonLake Immunotherapeutics Q1 Net Loss Widens | MT |
May. 07 | MoonLake Immunotherapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.24% | 2.57B | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- MLTX Stock
- News MoonLake Immunotherapeutics
- MoonLake Immunotherapeutics Reports Earnings Results for the Full Year Ended December 31, 2023